Control Cohort CTRL COH

Not Applicable

Recruiting

• Conditions: Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis
• Interventions: Biological: Collection of biological sample (blood and/or CSF)

• Registration Number: NCT05370079
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2022-05-06
• Study First Submitted QC: 2022-05-06
• Study First Posted: 2022-05-11
• Study Start: 2023-08-08
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-25
• Last Update Posted: 2024-01-26
• Primary Completion: 2028-08-08
• Study Completion: 2028-08-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

• patient with consent
• patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

Read More

Exclusion Criteria

• refusal consent
• patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
• patient under guardianship

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Control cohort	Collection of biological sample (blood and/or CSF)	Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

Primary Outcome Measures

Name	Time	Method
Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid)	15 minutes	Numbers of samples collected and patients included in the cohort

Secondary Outcome Measures

Name	Time	Method
Description of genetic analysis	Data collecting: 3 years Data analysis: 2 years	Number of new biomarkers (genetic) and specific HLA (human leucocyte antigen)

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Bron, France